Clinical Trial Update: Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use)

View source ↗

Summary

Clinical trial update describing expanded access use of CliniMACS CD34 TCR Alpha/Beta for allogeneic transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• CliniMACS CD34 TCR Alpha/Beta

Snippet

Sponsor: Victor Aquino | Conditions: Transplant-Related Disorder, GVH - Graft Versus Host Reaction | Status: AVAILABLE